Trial Information
Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
Inclusion Criteria:
- Early stage breast cancer patients taking adjuvant endocrine therapy (ie, tamoxifen,
anastrozole, letrozole, exemestane).
- Age ≥ 60 years
- Must have broadband internet access at home (to enable the base for the system to
communicate to the Vitality server).
- Must have a landline or mobile phone
Exclusion Criteria:
- Non-English speaking patients
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Assess the usability of the GlowCap system by patients
Outcome Description:
>60 years of age with early stage breast cancer.
Outcome Time Frame:
2 years
Safety Issue:
No
Principal Investigator
Tiffany Traina, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
10-183
NCT ID:
NCT01239251
Start Date:
November 2010
Completion Date:
November 2012
Related Keywords:
- Breast Cancer
- GlowCap
- adjuvant endocrine therapy
- Breast Neoplasms
Name | Location |
Memorial Sloan-Kettering Cancer Center 1275 York Avenue |
New York, New York 10021 |